Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Aspen Aerogels Inc . (NYSE:ASPN), a leader in aerogel technology, saw its stock tumble to a 52-week low of $9.09, reflecting a period of significant market headwinds for the company. Despite the current challenges, InvestingPro data shows impressive revenue growth of nearly 90% over the last twelve months, with sales reaching $452.7 million. Over the past year, Aspen Aerogels has experienced a notable decline, with its stock price falling by 31.57%. This downturn highlights the challenges faced by the company in a competitive and rapidly evolving industry. However, analysts maintain a bullish outlook, with seven analysts recently revising earnings estimates upward. According to InvestingPro analysis, the company appears undervalued at current levels, with additional insights available in the comprehensive Pro Research Report, which offers detailed analysis of 1,400+ top stocks.
In other recent news, Aspen Aerogels, Inc. reported its fourth-quarter results, which surpassed analyst estimates, with adjusted earnings per share of $0.14 and a revenue of $123.1 million, marking a 46% YoY increase. The company’s annual revenue for 2024 also showed impressive growth, reaching $452.7 million, a 90% YoY increase, with a net income of $13.4 million. Despite these positive results, the company has issued a weak guidance for Q1 2025, forecasting revenue between $75 million and $95 million, falling short of analyst projections of $104.2 million, and expecting a net loss per share between $0.18 and breakeven.
Aspen Aerogels has also announced a halt in the construction of its second aerogel manufacturing facility in Statesboro, Georgia, choosing instead to maximize capacity at its existing East Providence facility and leverage external manufacturing capabilities. These recent developments indicate a shift in the company’s operational strategy, potentially in response to the weaker Q1 guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.